Podcasts about pulmonary medicine

Learning Objectives:By the end of this series, listeners should be able to discuss:The physiologic rationale supporting the use of airway pressure release ventilation (APRV) in ARDS. The patient populations most likely to benefit from APRV.Key published evidence that informs our use of APRV in critical care.An expert approach to managing a patient with APRV.Next steps in research that will direct our understanding of the use of APRV in pediatric critical care.About our Guest: Dr. Palen Mallory is an assistant professor of pediatrics at Duke University and a pediatric intensivist at Duke Children's Hospital. She completed medical school at Virginia Commonwealth University, a pediatric residency at Emory University, and a critical care fellowship at Vanderbilt University. She is interested in respiratory care research, including ECMO, respiratory failure, and ARDS.Selected References:Mallory, P., & Cheifetz, I. (2020). A comprehensive review of the use and understanding of airway pressure release ventilation. Expert Review of Respiratory Medicine, 14(3), 307–315. https://doi.org/10.1080/17476348.2020.1708719Frawley, P. M., & Habashi, N. M. (2004). Airway pressure release ventilation and pediatrics: Theory and practice. Critical Care Nursing Clinics of North America, 16(3 SPEC. ISS.), 337–348. https://doi.org/10.1016/J.CCELL.2004.04.003Fredericks, A. S., Bunker, M. P., Gliga, L. A., Ebeling, C. G., Ringqvist, J. R. B., Heravi, H., Manley, J., Valladares, J., & Romito, B. T. (2020). Airway Pressure Release Ventilation: A Review of the Evidence, Theoretical Benefits, and Alternative Titration Strategies. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 14. https://doi.org/10.1177/1179548420903297APRV Guideline - EMCrit Project. (n.d.). Retrieved March 30, 2025, from https://emcrit.org/squirt/aprv/Andrews P, Shiber J, Madden M, Nieman GF, Camporota L, Habashi NM. Myths and Misconceptions of Airway Pressure Release Ventilation: Getting Past the Noise and on to the Signal. Front Physiol. 2022 Jul 25;13:928562. doi: 10.3389/fphys.2022.928562. PMID: 35957Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

Learning Objectives:By the end of this series, listeners should be able to discuss:The physiologic rationale supporting the use of airway pressure release ventilation (APRV) in ARDS. The patient populations most likely to benefit from APRV.Key published evidence that informs our use of APRV in critical care.An expert approach to managing a patient with APRV.Next steps in research that will direct our understanding of the use of APRV in pediatric critical care.About our Guest: Dr. Palen Mallory is an assistant professor of pediatrics at Duke University and a pediatric intensivist at Duke Children's Hospital. She completed medical school at Virginia Commonwealth University, a pediatric residency at Emory University, and a critical care fellowship at Vanderbilt University. She is interested in respiratory care research, including ECMO, respiratory failure, and ARDS.Selected References:Mallory, P., & Cheifetz, I. (2020). A comprehensive review of the use and understanding of airway pressure release ventilation. Expert Review of Respiratory Medicine, 14(3), 307–315. https://doi.org/10.1080/17476348.2020.1708719Frawley, P. M., & Habashi, N. M. (2004). Airway pressure release ventilation and pediatrics: Theory and practice. Critical Care Nursing Clinics of North America, 16(3 SPEC. ISS.), 337–348. https://doi.org/10.1016/J.CCELL.2004.04.003Fredericks, A. S., Bunker, M. P., Gliga, L. A., Ebeling, C. G., Ringqvist, J. R. B., Heravi, H., Manley, J., Valladares, J., & Romito, B. T. (2020). Airway Pressure Release Ventilation: A Review of the Evidence, Theoretical Benefits, and Alternative Titration Strategies. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 14. https://doi.org/10.1177/1179548420903297APRV Guideline - EMCrit Project. (n.d.). Retrieved March 30, 2025, from https://emcrit.org/squirt/aprv/Andrews P, Shiber J, Madden M, Nieman GF, Camporota L, Habashi NM. Myths and Misconceptions of Airway Pressure Release Ventilation: Getting Past the Noise and on to the Signal. Front Physiol. 2022 Jul 25;13:928562. doi: 10.3389/fphys.2022.928562. PMID: 35957Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

Guest: Jorge Nieva, MD Can the immune checkpoint inhibitor atezolizumab be safely administered subcutaneously at home for patients with non-small cell lung cancer (NSCLC)? That's the exact question an ongoing study is seeking to answer, and here to discuss the study's objective, design, and potential implications for home-based subcutaneous cancer therapies is Dr. Jorge Nivea. He's an Associate Professor of Clinical Medicine at the University of Southern California's Keck School of Medicine.

Guest: Jessica Shull, PhD Guest: Joshua Solomon, MD Host: Ryan Quigley Patients with pulmonary fibrosis often face anxiety and emotional distress that go unadressed during their care. Given this unmet need, a digital cognitive behavioral therapy (CBT) platform was designed to support emotional wellbeing alonside medical treatment. Mr. Ryan Quigley sits down with Drs. Jessica Shull and Joshua Solomon, who presented at the 2025 American Thoracic Society International Conference to explore how this platform may enhance quality of life, support therapy adherence, and integrate into routine care. Dr. Shull is the Director of Digital Health and a Clinical Science Liaison at Vicore Pharma, and Dr. Solomon is a Professor of Medicine in Pulmonary Care and the Director of the Interstitial Lung Disease Program at National Jewish Health.

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Anurag Singh, MD Guest: Adam H. Fox, MD, MSc Guest: Mariam Alexander, MD, PhD Despite the typically poor prognosis of extensive-stage small cell lung cancer, recent advancements are reshaping clinical perspectives on treatment. New and emerging options show promise for prolonged survival and improved quality of life. Join Drs. Gerard Silvestri, Adam Fox, Mariam Alexander, and Anurag Singh as they discuss how the therapeutic landscape is evolving for these patients. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Anurag Singh, MD Guest: Adam H. Fox, MD, MSc Guest: Mariam Alexander, MD, PhD Recent therapeutic advances are reshaping our approach to limited-stage small cell lung cancer. In this multidisciplinary discussion, Dr. Gerard Silvestri sits down with Drs. Adam Fox, Mariam Alexander, and Anurag Singh to explore the evolving standard of care and practical considerations for timely and effective care. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Guest: Divya Shankar, MD A recent study investigated whether pulse-dose corticosteroids offer a benefit over lower doses in managing acute exacerbations of idiopathic pulmonary fibrosis (IPF). Join Dr. Divya Shankar as she explains the real-world data, variability in prescribing patterns, and outcomes observed in different levels of care. Divya Shankar is an Assistant Professor of Medicine at Boston University Chobanian and Avedisian School of Medicine as well as a Pulmonary and Critical Care Physician at Boston Medical Center, and she spoke about this topic at the 2025 American Thoracic Society International Conference.

Guest: Isabel Bazan, MD, BA As race-neutral reference equations have become the standard in pulmonary function tests (PFTs), a recent study explored the potential impact of this change on diagnosis and treatment of severe asthma. Join Dr. Isabel Bazan as she dives into the data and explains its implications for patient categorization and access to care. Dr. Bazan is an Assistant Professor of Medicine at Yale School of Medicine, and she spoke about this topic at the 2025 American Thoracic Society International Conference.

Guest: Daniel Paul Vena, PhD A recent study explored whether lateral wall collapse can predict hypoglossal nerve stimulation efficacy in patients with obstructive sleep apnea (OSA). Join Dr. Daniel Vena as he explains the findings from this research and areas for future explanation. Dr. Vena is an Assistant Professor of Medicine at Brigham and Women's Hospital and Harvard Medical School, and he spoke about this topic at the 2025 American Thoracic Society International Conference.

Host: Diego Maselli, MD Guest: Monica Kraft, MD, FCCP Guest: Anju T Peters, MD, MSCI, FAAAAI IL-5 is a key driver of Type 2 inflammation in patients with severe asthma, promoting downstream effects like mucus plugging and epithelial barrier dysfunction. Given these impacts, targeted therapy with biologics can play a role in severe asthma management. Join Drs. Diego Maselli, Anju Peters, and Monica Kraft as they explore the impacts of IL-5 and share perspectives on patient selection and shared decision-making for targeted therapies. Dr. Maselli is a Professor of Medicine at the Long School of Medicine at UT Health in San Antonio. Dr. Peters is a Professor of Medicine and Associate Chief of Clinical Research and Practice Innovation at Northwestern Medicine in Chicago. Dr. Kraft is a System Chair of the Samuel Bronfman Department of Medicine and a Professor of Medicine at the Icahn School of Medicine at Mount Sinai Health Systems in New York. This episode of Deep Breaths: Updates from CHEST was supported by a non-promotional, non-CME educational program brought to you by CHEST in collaboration with and sponsored by GSK.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jason Ackrivo, MD, MSCE Guest: Bethany Lussier, MD Respiratory decline in patients with neuromuscular diseases and mitochondrial myopathies can be challenging to identify, especially because its early signs may be subtle and vary from person to person. However, knowing how to evaluate a patient's respiratory function is key to improving outcomes and quality of life. Joining Dr. Charles Turck to discuss this importance and provide recommendations for optimizing respiratory care are Drs. Jason Ackrivo and Bethany Lussier. Dr. Ackrivo is an Assistant Professor of Medicine in Pulmonary, Allergy, and Critical Care at the Hospital of the University of Pennsylvania, and Dr. Lussier is an Associate Professor of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Pulmonary and Critical Care Medicine.

Host: Nathan Falk, MD, MBA, FAAFP Guest: Megan Conroy, MD, MA(Ed), FCCP Patients with chronic obstructive pulmonary disease (COPD) often experience significant delays in diagnosis and treatment due to systemic gaps in management. A recent survey of 400 primary care and pulmonary clinicians uncovered patterns of fragmented care among both specialties. Join Dr. Nate Falk and Dr. Megan Conroy as they dive into the findings and explain how CHEST's COPD Toolkit can help clinicians address these gaps and provide a coordinated approach to COPD management. Dr. Falk is a board-certified family physician as well as a Professor and Founding Residency Director for Family Medicine at Florida State University in partnership with BayCare Health System. Dr. Conroy is a Chair and Assistant Professor in the Division of Pulmonary, Critical Care, and Sleep Medicine at The Ohio State University. This program is produced in partnership with the American College of CHEST Physicians and is supported by Regeneron Pharmaceuticals, Inc.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kaitlin Batley, MD Guest: Esra Caylan, MD Thymidine kinase 2 deficiency (TK2d) presents with a variability of symptoms, including respiratory, neurological, and ocular ones, making it difficult to diagnose. Because of this, a multidisciplinary care team that's tailored to each patient's needs is key to effectively identifying and treating this disease. Hear about the role of a multidisciplinary team and strategies for personalizing treatment with Drs. Kaitlin Batley and Esra Caylan. Dr. Batley is the Director of Pediatric Neuromuscular Medicine at Children's Health and an Assistant Professor at UT Southwestern Medical Center. Dr. Caylan is a pediatric pulmonologist at Children's Health and an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center.

Host: Nathan Falk, MD, MBA, FAAFP Guest: Ashwin Basavaraj, MD Early recognition and diagnosis of non-tuberculosis mycobacteria (NTM) and bronchiectasis are key for optimal patient management. However, these conditions are often misdiagnosed as COPD or asthma, leading to significant challenges and delays in treatment. Join Drs. Nate Falk and Ashwin Basavaraj as they share perspectives on accurately diagnosing NTM and bronchiectasis with early symptom recognition, a thorough patient history, and testing. Dr. Falk is a board-certified family medicine physician, a Professor and Founding Residency Director for Family Medicine at Florida State University in partnership with BayCare Health System, and the Assistant Dean for Graduate Medical Education at Florida State University. Dr. Basavaraj is an Associate Professor of Medicine at New York University Grossman School of Medicine, the Director of the Bronchiectasis and NTM Education Program at NYU Langone Health, and the Section Chief of Pulmonary, Critical Care, and Sleep Medicine at Bellevue Hospital Center. This program is produced in partnership with the American College of CHEST Physicians and is sponsored by Insmed Incorporated.

Guest: Nasser Altorki, MD Nasser Altorki, MD, chief of thoracic surgery at NewYork-Presbyterian and Weill Cornell Medicine, shares the results of a first-of-its-kind study evaluating low-dose radiation combined with immunotherapy for neoadjuvant treatment of non-small cell lung cancer (NSCLC) tumors. The dual-therapy treatment of durvalumab in combination with stereotactic body radiation was almost twice as effective at tumor killing compared to durvalumab alone. © 2025 NewYork-Presbyterian

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Bimaje Akpa, MD Clinical practice guidelines from the American College of Chest Physicians provide recommendations for managing respiratory complications in patients with neuromuscular diseases, which can help inform our evaluation and treatment decisions. Joining Dr. Charles Turck to break down key insights from the CHEST guidelines and their impacts on clinical practice is Dr. Bimaje Akpa. Dr. Akpa is an Assistant Professor of Medicine in the Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine at the University of Minnesota.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jason Ackrivo, MD, MSCE Respiratory complications are fairly common in patients with neuromuscular disorders, and given their vast impacts on a patient's prognosis and quality of life, it's critical to proactively detect and monitor any signs of respiratory decline. To learn more about the symptoms, impacts, and diagnosis of respiratory complications in patients with neuromuscular disorders, Dr. Charles Turck speaks with Dr. Jason Ackrivo. Not only is Dr. Ackrivo the Associate Director of the Fishman Program for Home Assisted Ventilation, but he's also an Assistant Professor of Medicine in Pulmonary, Allergy, and Critical Care at the Hospital of the University of Pennsylvania.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hank Mayer, MD Patients with neuromuscular conditions often exhibit respiratory symptoms that impact their airway clearance and gas exchange, making it increasingly difficult for them to breathe. However, effective assessment techniques and early intervention can help mitigate the progression of this dysfunction, potentially keeping patients from needing extended recovery time or even inpatient care. Joining Dr. Charles Turck to discuss the importance of informed, proactive intervention for respiratory symptoms in patients with neuromuscular conditions is Dr. Hank Mayer. Dr. Mayer is the Medical Director of the Pulmonary Function Laboratory at the Children's Hospital of Philadelphia and a Professor of Clinical Pediatrics at the University of Pennsylvania's Perelman School of Medicine.

Guest: Kathleen M. Buchheit, MD Guest: Joseph K. Han, MD Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with a low quality of life and increased healthcare utilization,1,2 and patients often continue to have severe symptoms despite therapy.​3 Understanding the role of underlying inflammatory pathways and epithelial dysfunction may help inform clinical decision making for these patients.​3,4 In this program, Dr Kathleen Buchheit and Dr Joseph Han share their insights on the pathophysiology of CRSwNP and how unaddressed underlying inflammation may contribute to a variety of challenges for patients. Dr Buchheit is an Assistant Professor of Medicine at Harvard Medical School, specializing in Allergy and Immunology. Dr Han is a Professor of Otolaryngology, the Chief for the Division of Rhinology and Endoscopic Sinus and Skull Base Surgery, and the Chief of the Division of Allergy at Eastern Virginia Medical School in Norfolk, Virginia. References: Mullol J, et al. J Allergy Clin Immunol Pract. 2022;10:1434-1453.e9 Bhattacharyya N, et al. Laryngoscope. 2019;129:1969-1975. van der Veen J, et al. Allergy. 2017;72:282-290. Laidlaw TM, et al. J Allergy Clin Immunol Pract. 2021;9:1133-1141. ©2024 Amgen and AstraZeneca. All rights reserved.US-96000 Last Updated 12/24

CME credits: 0.50 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-safety-of-sodium-oxybate-in-treating-narcolepsy/29457/ Sodium content and the disruption associated with the twice-nightly dosing of sodium oxybate are common concerns when treating patients with narcolepsy. Is sodium content truly a risk factor for cardiovascular sequelae in patients with narcolepsy? Does twice-nightly dosing lead to medically unacceptable dosing errors? Join Drs. Sally Ibrahim and Clete Kushida as they dive into these questions and provide actionable answers for you to use in your clinical practice.=

In this brief video, learn more about growing evidence supporting the key role of airway epithelium dysfunction in driving inflammation in CRSwNP. ©2025 Amgen and AstraZeneca. All rights reserved.US-94728 Last Updated 1/25

Host: Jacob Sands, MD Guest: Julia Rotow, MD In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, the standard second-line therapy is docetaxel, but this can have poor response rates. That's why the DESTINY-Lung03 trial examined the safety and efficacy of trastuzumab deruxtecan in patients with pretreated HER2-overexpressing non-squamous NSCLC. Here with Dr. Jacob Sands to share the findings from part 1 of this trial is thoracic medical oncologist Dr. Julia Rotow.

CME credits: 0.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-diagnosis-management-and-updates-chairpersons-perspective/26626/ During a satellite symposium at the AHA 2024 Annual Meeting, experts reviewed the role of novel disease-modifying therapies (DMTs) in treating and managing pulmonary hypertension (PH) and the impact of current PH treatments vs novel DMTs. They also discussed how to identify appropriate patients for DMTs and strategies to customize treatment with risk-based assessments. In addition, highlights from the 7th World Symposium in PH were discussed. Tune in to keep up! =

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Laura Alder, MD The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it's important to identify biomarkers that can predict a patient's response to therapy. That's why the phase 1b TROPION-LUNG02 trial examined the effectiveness of Dato-DXd and HER3-DXd in the presence of predictive biomarkers. Joining Dr. Charles Turck to discuss the trial's findings and implications is Dr. Laura Alder, Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina.

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Docetaxel alone or in combination with ramucirumab is the current standard of care for the second-line treatment of non-small cell lung cancer (NSCLC), but there are several limitations of docetaxel-containing regimens. That's why there's interest in identifying new therapies like datopotamab deruxtecan (Dato-DXd), which was found to improve overall survival based on an interim analysis. But what are the latest findings? Here to share the final overall survival data on Dato-DXd from the TROPION-Lung01 trial are Drs. Jacob Sands and Aaron Lisberg, who worked together on this research that was presented at the 2024 World Conference on Lung Cancer.

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That's why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share the results presented at the 2024 ESMO Congress is thoracic medical oncologist Dr. Aaron Lisberg.

Host: Jacob Sands, MD Guest: Alex Spira, MD, PhD, FACP Valemetostat is a novel therapy that's demonstrated clinical efficacy and safety across multiple hematologic malignancies, but what role might it have in treating patients with advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC)? To find out, an upcoming trial is examining the efficacy and safety of combining valemetostat and datopotamab deruxtecan (Dato-DXd). Here with Dr. Jacob Sands to talk about the study's design and next steps is Dr. Alex Spira, Director of the Thoracic and Phase I Program at Virginia Cancer Specialists Research Institute and a Clinical Assistant Professor at Johns Hopkins.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Thomas Egenod, MD In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2 study is evaluating the efficacy and safety of combining durvalumab, chemotherapy, and novel agents in the neoadjuvant setting as well as combining durvalumab with novel agents in the adjuvant setting. Joining Dr. Charles Turck to share the preliminary results regarding the safety, pathological complete response, and major pathological response rates of these two approaches is study investigator Dr. Thomas Egenod, who presented the NeoCOAST-2 study at the 2024 World Conference on Lung Cancer.

CME credits: 1.00 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/risk-assessment-in-pulmonary-hypertension-practice-trends-and-updates/28867/ Hear about the latest updates in risk assessment and find out how you can accurately use risk stratification to categorize patients in a timely manner to improve both their care and quality of life. You'll also discover changing practice trends and the latest evidence that may impact your practice. =

CME credits: 1.00 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-management-practice-trends-and-updates/28868/ The landscape of medication management for patients with pulmonary hypertension (PH) has significantly changed with the introduction of combination therapy and recent trial data. This activity presents the latest evidence and breaks down new approaches to the management of PH. Join our experts to find out how your daily practice will be affected.=

CME credits: 1.00 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-comorbidities-with-pah-and-group-2-ph/28869/ Providers face challenges when it comes to pulmonary hypertension (PH), especially when distinguishing between PAH with comorbidities and group 2 PH. In addition, PH resulting from left heart disease may further complicate diagnosis and treatment. Hear what the experts have to say about identifying and treating these patient populations. =

CME credits: 0.25 Valid until: 16-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/copd-care-partnership-between-primary-care-and-pulmonary-providers/26927/ Primary care providers can play a pivotal role in a patient's COPD diagnosis by looking out for signs and symptoms and referring patients to pulmonologists when appropriate. The goal of this activity is to educate clinicians about managing patients with COPD symptoms and facilitating earlier diagnosis. Hear both primary care and pulmonary perspectives on diagnostic strategies. CLINICIANS: To access additional resources for COPD diagnosis, visit chestnet.org/timely- diagnosis-COPD or scan the QR code. =

Host: Jacob Sands, MD Guest: Marina Garassino, MD Datopotamab deruxtecan (Dato-DXd) is a second-line antibody drug conjugate that could lead to improved progression-free survival in patients with advanced or metastatic non-small cell lung cancer. Given these potential benefits, it's important to identify biomarkers that may predict a patient's response to Dato-DXd, which was the focus of recent research presented at the 2024 World Conference on Lung Cancer. Here with Dr. Jacob Sands to discuss a new biomarker for TROP2 is Dr. Marina Garassino, Professor of Medicine and Director of the Thoracic Oncology Program at the University of Chicago.

In this episode of Lung Cancer Considered, Dr. Aakash Desai moderates a discussion in Hindi on management of non-small cell lung cancer and small cell lung cancer in the Indian context. The group discusses advances in immunotherapy in resectable NSCLC and other new treatments on the horizon. Host: Dr. Aakash Desai is an Assistant Professor of Medicine at the O'Neal Comprehensive Cancer Center, University of Alabama in Birmingham, Alabama. He is the Co-Chair, Lung Cancer Working Group, and Associate Director, Phase 1 and Precision Oncology Program. Guest: Dr. Navneet Singh is a Professor, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education & Research (PGIMER) in Chandigarh, India. Guest: Dr. Sewanti Limaye is the Director of Medical & Precision Oncology and Director of Clinical and Translational Oncology Research at the Sir HN Reliance Foundation Hospital and Research Centre in Mumbai, India. She is the Co-Chair of the Asia Pacific Coalition Against Lung Cancer.

CME credits: 0.50 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/breathing-through-the-burden-of-copd/27032/ Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician's role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

CME credits: 0.50 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/molecular-mechanisms-of-copd/27033/ Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician's role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

CME credits: 0.50 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-copd-from-symptoms-to-assessment-the-2024-gold-standards/27034/ Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician's role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

CME credits: 0.50 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/insights-to-pharmaceutical-approaches-in-copd/27036/ Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician's role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

CME credits: 0.50 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/putting-theory-into-practice-mastering-management-of-copd/27037/ Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician's role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

CME credits: 0.50 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/going-beyond-todays-assessments-to-confirm-copd-are-biomarkers-key/27035/ Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician's role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

CME credits: 1.00 Valid until: 17-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-for-advanced-practice-providers-risk-stratification-and-diagnosis-to-enhance-quality-of-care-and-outcomes/27146/ This program focuses on early symptom identification and timely diagnosis in patients with pulmonary hypertension (PH). Learn how appropriate risk stratification can facilitate the effective management of PH. Our experts also stress the importance of asking the right questions and offer strategies for achieving well-rounded communication with patients and their caregivers.=

CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/bridging-distances-in-pah-bringing-best-practices-to-the-people-through-telemonitoring/24051/ Pulmonary Arterial Hypertension (PAH) requires a personalized, multidisciplinary approach, which is often lacking in remote regions due to limited access to specialized care and resources. The scarcity of specialized PH centers forces reliance on general practitioners, further hampered by geographic isolation and constrained resources. These limitations make it difficult for healthcare providers to stay updated on new treatments, guidelines, and clinical trial data. To address these gaps, a strategic initiative is needed to enhance early detection, deliver insights on novel therapies, and promote multidisciplinary care through telementoring, aiming to improve PAH management in underserved rural areas.=

CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/updates-from-the-7th-world-symposium-task-force/24597/ The 7th World Symposium Task Force on Pulmonary Hypertension focused on the standard of care, best practices, and emerging clinical data in the treatment of pulmonary hypertension (PH). For the first time, the 2024 Symposium started with patients' perspectives, acknowledging the respect and importance that should be given to patients' priorities. The translational aspects of modern pulmonary vascular research were highlighted, as were transplantation, bridging and support technologies, palliative care, management of pregnant women with PH, specificities of pediatric care, and the benefits of emerging multimodality imaging techniques and novel technologies. Tune in to get the details and improve care for your patients today! =

CME credits: 1.00 Valid until: 11-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancing-cystic-fibrosis-addressing-disparities-challenging-perceptions-and-innovating-patient-centered-care/24487/ Cystic Fibrosis (CF) care faces challenges from health disparities, limited access, and unintended bias, affecting patient outcomes. This CME program aims to equip healthcare professionals with the skills needed to overcome these barriers and provide equitable care for all CF patients. It covers telehealth strategies, best practices for transitioning patients from pediatric to adult care, and managing co-morbidities. The program also explores how evolving treatments impact patient outcomes.=

CME credits: 0.25 Valid until: 04-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/navigating-copd-from-symptom-recognition-to-emerging-treatment-strategies/26928/ Listen in as Farrukh Abbas, MD, FCCP, and Megan Conroy, MD, MAEd, FCCP, discuss the role of the care team in COPD diagnosis, recent changes in classifications and updates to the GOLD guidelines, how triple-inhaler therapies and biologics can be used to treat patients with COPD, and more. Since the time of this recording, the FDA has recently approved dupilumab as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) with type 2 inflammation. =

CME credits: 0.75 Valid until: 02-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-role-of-met-tkis-in-nsclc/17986/ The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and acceptable safety profiles. In this activity, our experts assess the role of the role of MET gene aberrations in NSCLC and optimal testing modalities, as well as the clinical evidence supporting the use of MET TKIs and the potential role of these therapies in other subsets of disease. =

On the second August episode of JHLT: The Podcast, the Digital Media Editors discuss a paper from the August issue of JHLT, entitled “A modular simulation framework for organ allocation.”The episode is hosted by Digital Media Editor Erika Lease, MD, FCCP, a transplant pulmonologist from the University of Washington.   The guests for this episode are first author Johnie Rose, MD, PhD, of the Center for Community Health Integration at Case Western Reserve University School of Medicine, and lead author Maryam Valapour, MD, MPP, of the Department of Pulmonary Medicine at the Cleveland Clinic.   In the episode, Drs. Rose and Valapour share the findings from their study, and tackle questions about the limitations of simulation models, what makes their COMET model different from past Simulation Allocation Models (SAMs), and why they made the project open-source.   Follow along at www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.   Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

"Don't get furious, get curious!" is where we end up at - listen in to hear about whittling, making meaning, and avoiding burnout.  This is Part 2 with Dr. Dean Gianakos where we focus more on the medical humanities. Dr. Dean Gianakos MD, FACP is currently Chief Academic Officer at Centra Health, a Central Virginia regional healthcare system. Wellness is important to him, and he has been chairman of Centra's Physician Wellness Committee. He is trained as an internist with previous certifications in Pulmonary Medicine as well as Hospice and Palliative Medicine, and he has taught many family medicine residents and medical students for almost 3 decades. Dr. Gianakos is interested in the medical humanities as well as end-of-life care, the patient-physician relationship, and communication. He is currently on the editorial board of The Pharos, a medical humanities journal. He is also a writer, and he has written, “Practicing medicine can be addictive. The daily praise and gratitude from patients feed the fragile egos of physicians.” Links to a few of his articles: the lonely physician, Whittling: The Last Class, leadership.

Hello and welcome to The Relatable Voice podcast. Today, we are on our way to Upstate New York to chat with Paul Joel. Paul is an accomplished author and a board-certified Internal and Pulmonary Medicine physician. He completed his fellowship in Pulmonary Medicine at Massachusetts General Hospital/Harvard, demonstrating his dedication to the field. His latest book, ‘A Man Like You and Me: A Supernatural Adventure Story,' is now available. Find out more at: https://pauljoelbook.com/

Dr. Dean Gianakos has been practicing medicine for almost 3 decades. He has many interests, including leadership skills, communication, and medical humanitis. In this first episode with Dr. Gianakos, we cover the DiSC assessment of leadership styles and how emotional intelligence is key to good leadership. He also touches on difficult conversations and how we can get better at them. Dr. Dean Gianakos MD, FACP is currently Chief Academic Officer at Centra Health, a Central Virginia regional healthcare system.  He is trained as an internist with previous certifications in Pulmonary Medicine as well as Hospice and Palliative Medicine,